Foamix Pharmaceuticals to Release Fiscal Year 2016 Financial Results and Host Conference Call & Webcast on Wednesday, February 22

February 7, 2017 at 4:05 PM EST

REHOVOT, Israel, and BRIDGEWATER, New Jersey, Feb. 7, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report its financial results for the year ended December 31, 2016 on Tuesday, February 21st after market close, and will host a corporate update conference call and webcast on Wednesday, February 22nd, at 8:30am Eastern Time.



Conference Call & Webcast

Wednesday, February 22nd  @ 8:30am Eastern Time

Toll Free:                     888-278-8446

International:               913-312-1473

Conference ID:            6799077


Replays, through March 8th:

Toll-Free:                     844-512-2921

International:               412-317-6671

Conference ID:            6799077


About Foamix Pharmaceuticals Ltd.

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.

Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.

For more information, please visit



US Investor Relations

Ilan Hadar, CFO           

Michael Rice

Foamix Pharmaceuticals Ltd.      

LifeSci Advisors, LLC






To view the original version on PR Newswire, visit:

SOURCE Foamix Pharmaceuticals Ltd.